The U.S. Food and Drug Administration has approved tbo-filgrastim to treat severe neutropenia. Triggered by certain chemotherapy drugs, neutropenia "is characterized by a decrease in infection-fighting white blood cells called neutrophils." Intended for adults who do not have blood or bone marrow cancer, patients receiving tbo-filgrastim recovered from severe neutropenia in 1.1 days, compared to 3.8 days among those administered a placebo.
To read more about this study, click here.
No comments:
Post a Comment